Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorZhao Jun
About this trial
Investigating the Clinical Value of Tumor Antigen-Specific T Cells and Immune Cell Balance in Peripheral Blood of Non-Small Cell Lung Cancer Patients for Prognostic Evaluation.
Eligibility criteria
Qualifiers
Age 18 to 80 years.
Diagnosed with primary non-small cell lung cancer (NSCLC) and scheduled to undergo curative lung resection at the Department of Thoracic Surgery of our institution.
Postoperative pathological stage is IB (with tumor size >4cm or high-risk factors: poor differentiation, vascular invasion, visceral pleural invasion, sub-lobar resection, etc.), IIA, IIB, or IIIB (according to the AJCC 8th edition).
ECOG performance status of 0 or 1.
Disqualifiers
Received any neoadjuvant therapy prior to surgery.
History of other active malignancies.
Diagnosed with severe autoimmune diseases, active infections, or immunodeficiency disorders.
Presence of severe cardiac, hepatic, or renal dysfunction.
Trial design
Treatments tested in this trial
- Preoperative Peripheral Blood Immune Marker Analysis.
Treatment groups
No treatment groups listed
Sponsors and collaborators
Zhao Jun
Lead sponsor
The First Affiliated Hospital of Soochow University
Sponsor institution
Source ClinicalTrials.gov